Chemed Co. (CHE) Receives $324.00 Average Target Price from Brokerages
Chemed Co. (NYSE:CHE) has earned an average rating of “Buy” from the five research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $324.00.
A number of equities analysts have recently commented on the company. Bank of America assumed coverage on Chemed in a report on Friday, October 12th. They issued a “buy” rating and a $390.00 price objective on the stock. Zacks Investment Research upgraded Chemed from a “hold” rating to a “buy” rating and set a $310.00 price objective on the stock in a report on Friday, January 4th.
Shares of NYSE:CHE opened at $297.94 on Friday. The company has a current ratio of 1.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.23. Chemed has a 12-month low of $243.95 and a 12-month high of $335.99. The stock has a market capitalization of $4.75 billion, a price-to-earnings ratio of 26.12, a price-to-earnings-growth ratio of 1.69 and a beta of 1.23.
In other news, insider Nicholas Michael Westfall sold 5,709 shares of the firm’s stock in a transaction dated Tuesday, December 11th. The stock was sold at an average price of $301.75, for a total value of $1,722,690.75. Following the transaction, the insider now directly owns 16,052 shares in the company, valued at approximately $4,843,691. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Naomi C. Dallob sold 5,500 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $317.23, for a total value of $1,744,765.00. Following the sale, the vice president now owns 11,122 shares in the company, valued at $3,528,232.06. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,662 shares of company stock worth $7,259,293. Company insiders own 4.82% of the company’s stock.
Large investors have recently made changes to their positions in the stock. First Hawaiian Bank raised its holdings in shares of Chemed by 21.3% during the 4th quarter. First Hawaiian Bank now owns 290 shares of the company’s stock valued at $82,000 after buying an additional 51 shares during the period. Cerebellum GP LLC purchased a new stake in shares of Chemed during the 3rd quarter valued at about $148,000. Tower Research Capital LLC TRC raised its holdings in shares of Chemed by 70.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 544 shares of the company’s stock valued at $175,000 after buying an additional 224 shares during the period. Franklin Resources Inc. purchased a new stake in shares of Chemed during the 3rd quarter valued at about $225,000. Finally, We Are One Seven LLC purchased a new stake in shares of Chemed during the 3rd quarter valued at about $228,000. Institutional investors and hedge funds own 87.85% of the company’s stock.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Featured Article: Different Types of Derivatives
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.